Psychedelic Medical Intervention
Investment Fund
Fund Size
USD $20M+
Target geography
USA, Canada, EU, Israel
Average Ticket
USD $500K-2M per deal
Target market
Psychedelic medicine
FUND PROFILE
Research is inadequate to the need
Existing treatments are not fully effective for the majority of patients
PROBLEM
One billion people are directly affected
The World is Suffering from a Mental Health Pandemic, with increasing rates of depression, anxiety, and addiction-related problems
Liberalization is Expanding
Regulation is on the Way
SOLUTION
Clinical Results are Impressive
Usage of Psychedelics for Psychiatric Conditions will lead to a major breakthrough in the treatment of mental health
OUR FOCUS
We primarily target companies with medications that are at an early stage of clinical development (preclinical or Phase I), which offers attractive entry valuations and feasible exiting time frames
for optimal capital return
OUR PORTFOLIO
TEAM
Partner
Co-founder of Bright Box
Ken Belotsky
Co-founder of BrightConsult
Partner
Owns a psychiatric clinic in NYC
Stuart Seidman
Teaches psychiatry at the Chaim Sheba Medical Center
Partner
Baring Vostok Capital Partners for more than 15 years
Vadim Uzberg
Eagle Venture Partners, a private equity fund
Completed residency training
in psychiatry, a fellowship in psychopharmacology, and was an attending psychiatrist and researcher at Columbia University in NYC
As a private investor did more than 30 transactions with early- and late-stage companies in the US, Israel, EU
LinkedIn Profile →
LinkedIn Profile →
LinkedIn Profile →
15 years in managing startups:
LEAVE AN APPLICATION
and we will contact you
* By clicking the button you consent to the processing of personal data.
Cayman Islands at PO Box 309,
Ugland House, Grand Cayman, KY1-1104, Cayman Islands
Leave an application and we will contact you
By clicking the button you consent to the processing
of personal data.